Anjarium: a hybrid approach to non-viral gene therapy

Switzerland-based Anjarium believes its platform using lipid nanoparticles and extracellular vesicles can help create non-viral gene therapies that can find a niche in the market, addressing challenges faced by others in the gene therapy sector.

Anjarium Biosciences AG revealed its CHF55.5 million ($60.3 million) series A round Thursday. Abingworth and Gimv led the round alongside Omega Funds, Pfizer Ventures and Citadel’s Surveyor Capital...